ketamine and Acute Post-Traumatic Stress Disorder studies

Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.

Research Excerpts

Excerpt	Relevance	Reference
"The N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder."	9.24	Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. ( Anderson-Fahey, B; Glue, P; Gray, A; Harland, S; Le Nedelec, M; McNaughton, N; Medlicott, NJ; Neehoff, S, 2017)
" We have previously shown that a single dose of ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, is associated with a rapid reduction in depressive symptom severity and SI in patients with treatment-resistant depression."	9.20	Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. ( Brallier, JW; Charney, DS; Collins, KA; DeWilde, KE; Goodman, WK; Iacoviello, BM; Iosifescu, DV; Kautz, M; Kim, J; Lapidus, KA; Lener, M; Murrough, JW; Perez, AM; Price, RB; Rodriguez, GJ; Soleimani, L; Stern, JB, 2015)
"Veterans receiving ketamine treatment ( across both IN-(S)-ketamine and IV-(R,S)-ketamine) showed significant reductions in both the Patient Health Questionnaire-9 (PHQ-9), a self-report scale measuring depression symptoms (rm ANOVA F(14,42) = 12."	8.12	Response to intravenous racemic ketamine after switch from intranasal (S)-ketamine on symptoms of treatment-resistant depression and post-traumatic stress disorder in Veterans: A retrospective case series. ( Artin, H; Baker, DG; Bentley, S; Bismark, A; De Peralta, S; Lee, EE; Liu, F; Martis, B; Mehaffey, E; Mishra, J; Printz, D; Ramanathan, D; Sojourner, K, 2022)
"The N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder."	5.24	Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. ( Anderson-Fahey, B; Glue, P; Gray, A; Harland, S; Le Nedelec, M; McNaughton, N; Medlicott, NJ; Neehoff, S, 2017)
" We have previously shown that a single dose of ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, is associated with a rapid reduction in depressive symptom severity and SI in patients with treatment-resistant depression."	5.20	Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. ( Brallier, JW; Charney, DS; Collins, KA; DeWilde, KE; Goodman, WK; Iacoviello, BM; Iosifescu, DV; Kautz, M; Kim, J; Lapidus, KA; Lener, M; Murrough, JW; Perez, AM; Price, RB; Rodriguez, GJ; Soleimani, L; Stern, JB, 2015)
"Veterans receiving ketamine treatment ( across both IN-(S)-ketamine and IV-(R,S)-ketamine) showed significant reductions in both the Patient Health Questionnaire-9 (PHQ-9), a self-report scale measuring depression symptoms (rm ANOVA F(14,42) = 12."	4.12	Response to intravenous racemic ketamine after switch from intranasal (S)-ketamine on symptoms of treatment-resistant depression and post-traumatic stress disorder in Veterans: A retrospective case series. ( Artin, H; Baker, DG; Bentley, S; Bismark, A; De Peralta, S; Lee, EE; Liu, F; Martis, B; Mehaffey, E; Mishra, J; Printz, D; Ramanathan, D; Sojourner, K, 2022)
"Patients with severe burns typically undergo multiple surgeries, and ketamine is often used as part of the multimodal anesthetic regimen during such surgeries."	3.80	The intraoperative administration of ketamine to burned U.S. service members does not increase the incidence of post-traumatic stress disorder. ( Fowler, M; Garza, TH; Maani, CV; McGhee, LL; Petz, LN; Slater, TM, 2014)
"Contrary to expectations, patients receiving perioperative ketamine had a lower prevalence of PTSD than soldiers receiving no ketamine during their surgeries despite having larger burns, higher injury severity score, undergoing more operations, and spending more time in the ICU."	3.74	The correlation between ketamine and posttraumatic stress disorder in burned service members. ( Black, IH; Garza, TH; Gaylord, KM; Maani, CV; McGhee, LL, 2008)
"27 individuals diagnosed with PTSD were randomly assigned to receive either ketamine (0."	3.30	Long term structural and functional neural changes following a single infusion of Ketamine in PTSD. ( Amen, S; Duek, O; Gordon, C; Harpaz-Rotem, I; Kelmendi, B; Korem, N; Krystal, JH; Levy, I; Li, Y; Milne, M, 2023)
"Veterans and service members with PTSD (n = 158) who failed previous antidepressant treatment were randomized to 8 infusions administered twice weekly of intravenous placebo (n = 54), low dose (0."	3.11	Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. ( Abdallah, CG; Ahn, KH; Averill, LA; Baltutis, EJ; Brundige, A; Bryant, CE; Burson, RR; D'Souza, D; Gueorguieva, R; Guthmiller, KB; Hoch, MB; Keane, TM; Krystal, JH; Lautenschlager, KA; Litz, BT; López-Roca, AL; Martini, B; McCallin, JP; Mintz, J; Murff, W; Peterson, AL; Petrakis, IL; Purohit, P; Ranganathan, M; Roache, JD; Sherif, MA; Shiroma, PR; Southwick, SM; Souza, SE; Timchenko, A; Williamson, DE; Young-McCaughan, S, 2022)
"Ketamine infusions were well tolerated overall, without serious adverse events."	3.01	A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. ( Bevilacqua, L; Brallier, J; Charney, DS; Collins, AB; Collins, KA; Corniquel, M; Costi, S; Feder, A; Glasgow, AM; Govindarajulu, U; Horn, SR; Jha, MK; Kautz, M; Murrough, JW; Pietrzak, RH; Rutter, SB, 2021)
"Improvements in PTSD severity were associated with increased functional connectivity between the ventromedial prefrontal cortex (vmPFC) and amygdala during emotional face-viewing (change score retained in model with minimum predictive error in left-out subjects, standardized regression coefficient [β] = 2."	3.01	Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence. ( Brallier, J; Charney, DS; Collins, AB; Collins, KA; Corniquel, M; Costi, S; Feder, A; Glasgow, AM; Horn, SR; Jha, MK; Kautz, M; Murrough, JW; Norbury, A; Rutter, SB; Shin, LM, 2021)
"Posttraumatic stress disorder (PTSD) is a debilitating disorder with limited medication treatment options."	2.90	Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial. ( Abdallah, CG; Amoroso, T; Averill, LA; Gueorguieva, R; Guthmiller, K; Keane, TM; Krystal, JH; Lautenschlager, K; Litz, BT; López-Roca, AL; Martini, B; Mintz, J; Peterson, AL; Roache, JD; Southwick, SM; Williamson, DE; Young-McCaughan, S, 2019)
"Post-traumatic stress disorder (PTSD) is a chronic and debilitating condition that is often refractory to standard frontline antidepressant therapy."	2.87	d-Serine is a potential biomarker for clinical response in treatment of post-traumatic stress disorder using (R,S)-ketamine infusion and TIMBER psychotherapy: A pilot study. ( Mitrev, L; Moaddell, R; Pradhan, B; Wainer, IW, 2018)
"Posttraumatic stress disorder (PTSD) has long-lasting debilitating symptoms."	2.82	The safety and efficacy of ketamine NMDA receptor blocker as a therapeutic intervention for PTSD review of a randomized clinical trial. ( Chao, T; Jain, S; Jumaili, WA; Kubosumi, A; Trivedi, C, 2022)
"Post-traumatic stress disorder (PTSD) is an anxiety disorder with manifestations somatic resulting from reliving the trauma."	2.82	Evidence for the beneficial effect of ketamine in the treatment of patients with post-traumatic stress disorder: A systematic review and meta-analysis. ( Albuquerque, TR; Almeida, TM; Cordeiro, Q; Delmondes, GA; Lisboa, KWSC; Macedo, LFR; Menezes, IRA; Rolim Neto, ML; Uchida, RR, 2022)
"Ketamine infusion was associated with significant and rapid reduction in PTSD symptom severity, compared with midazolam, when assessed 24 hours after infusion (mean difference in Impact of Event Scale-Revised score, 12."	2.79	Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. ( Aan Het Rot, M; Charney, DS; Feder, A; Iosifescu, D; Kirkwood, K; Lapidus, KA; Morgan, JE; Murrough, JW; Parides, MK; Perez, AM; Saxena, S; Wan, LB, 2014)
"Posttraumatic stress disorder (PTSD) is a devastating medical illness, for which currently available pharmacotherapies have poor efficacy."	2.72	Ketamine for post-traumatic stress disorders and it's possible therapeutic mechanism. ( Asim, M; Hao, B; Wang, B; Wang, X, 2021)
"Ketamine has been receiving increasing attention as an interventional treatment modality in psychiatry, especially among refractory conditions, including major depressive disorder."	2.66	Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: a review of the literature. ( Banov, MD; Dunn, T; Szabo, ST; Young, JR, 2020)
"While research on ketamine for PTSD is still in its early stages, it brings about the promise of novel and more effective treatments for this disabling condition."	2.66	The emergence of ketamine as a novel treatment for posttraumatic stress disorder. ( Charney, DS; Feder, A; Rutter, SB; Schiller, D, 2020)
"Posttraumatic stress disorder (PTSD) is often a chronic condition, despite the availability of various evidence-based treatment options."	2.66	[Psychedelics in the treatment of PTSD]. ( Bostoen, T; Breeksema, JJ; Krediet, E; Schoevers, RA; van den Brink, W; Vermetten, E, 2020)
"Recently, emergence delirium (ED) has been associated with patients with posttraumatic stress disorder (PTSD)."	2.58	Subanesthetic-Dose Ketamine to Decrease Emergence Delirium in the Surgical Patient With Posttraumatic Stress Disorder. ( Hintzsche, K, 2018)
"The rationale for the use of MDMA in PTSD and SUD is being extended to a broader beneficial "psychedelic effect," which is supporting further clinical investigations, in spite of the lack of mechanistic hypothesis."	2.58	Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine. ( Chiamulera, C; Fattore, L; Fumagalli, G; Piva, A; Zanda, MT, 2018)
"As TR-PTSD has a marked public health burden and significant limitations in terms of treatment interventions, a thorough assessment of current strategies is required."	2.53	Nonconventional interventions for chronic post-traumatic stress disorder: Ketamine, repetitive trans-cranial magnetic stimulation (rTMS), and alternative approaches. ( Kluewer D'Amico, J; Makani, R; Parikh, T; Pradhan, B, 2016)
"We report a case of a child with PTSD and episodes of severe aggression and emotional dysregulation that were refractory to multiple medical and behavioral interventions."	2.52	Remission From Behavioral Dysregulation in a Child With PTSD After Receiving Procedural Ketamine. ( Cullen, KR; Donoghue, AC; Roback, MG, 2015)
"Posttraumatic stress disorder (PTSD), a disabling and chronic condition after exposure to an extreme traumatic event, affects approximately 8% of the population worldwide."	1.91	Age-related impairment in fear memory extinction is restored by ketamine in middle-aged mice. ( Li, H; Shao, H; Wang, H; Xue, Q; Zhao, Y, 2023)
"Post-traumatic stress disorder (PTSD) is a complex, chronic psychiatric disorder typically triggered by life-threatening events and, as yet, lacks a specialized pharmacological treatment."	1.91	The potential role of GSK-3β signaling pathway for amelioration actions of ketamine on the PTSD rodent model. ( Hu, X; Li, C; Li, Z; Lian, B; Liu, L; Lu, G; Sun, L; Sun, Y; Wang, L; Wang, Z; Yue, K; Zhou, G, 2023)
" The current study investigated 1) changes in neurocognitive performance after a repeated ketamine dosing regimen and 2) baseline neurocognitive performance as a predictor of ketamine treatment effect."	1.72	Neurocognitive effects of repeated ketamine infusions in comorbid posttraumatic stress disorder and major depressive disorder. ( Albott, CS; Erbes, C; Lim, KO; Shiroma, PR; Thuras, P; Tye, SJ; Wels, J, 2022)
"Post-traumatic stress disorder (PTSD) is a devastating mental illness with high morbidity and major social and economic burden."	1.72	Ketamine attenuates the PTSD-like effect via regulation of glutamatergic signaling in the nucleus accumbens of mice. ( Asim, M; Hao, B; Liang, YM; Wang, XG; Waris, A, 2022)
"Psychiatric (n = 29; 15 PTSD, 14 MDD) and sex- age- and IQ matched HC (n = 29) groups were recruited from the community."	1.62	Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder. ( Davis, MT; DellaGiogia, N; Esterlis, I; Maruff, P; Pietrzak, RH, 2021)
"Post-traumatic stress disorder (PTSD) is a debilitating mental disease with high morbidity and major social and economic relevance."	1.62	Effect of ketamine on mood dysfunction and spatial cognition deficits in PTSD mouse models via HCN1-BDNF signaling. ( Du, Y; Du, Z; Li, C; Li, Q; Sun, H; Sun, L; Wang, A; Wang, Y; Zhang, W; Zhang, X; Zhao, Y, 2021)
"Post-traumatic stress disorder (PTSD) is a chronic and disabling condition arising after exposure to a severe traumatic event, which affects approximately eight percent of the population."	1.56	Ketamine reverses the impaired fear memory extinction and accompanied depressive-like behaviors in adolescent mice. ( Chen, WY; Lu, K; Lv, BJ; Wang, Y; Wang, YH; Wei, MD, 2020)
"No differences in PTSD screening risk or symptom levels between ketamine exposed and nonexposed were found."	1.56	Ketamine Administration During Hospitalization Is Not Associated With Posttraumatic Stress Disorder Outcomes in Military Combat Casualties: A Matched Cohort Study. ( Buckenmaier, CC; Highland, KB; Kemezis, PA; Soumoff, AA; Spinks, EA, 2020)
"Conclusions A PTSD flashback may occur from ketamine sedation in patients with a past history of military experience and can be a manifestation of psychologic adverse effects of ketamine."	1.51	Post-traumatic stress disorder or emergence phenomena? A case of psychomotor agitation after procedural sedation and analgesia. ( Akbari, H; Bahreini, M; Jalali, A, 2019)
"Ketamine has been shown to be an effective treatment for numerous mental health disorders, although research on its efficacy in combat-related PTSD in veterans is very limited."	1.51	High-dose ketamine infusion for the treatment of posttraumatic stress disorder in combat veterans. ( Bonnett, CJ; Jain, R; Ross, C; Wolfson, P, 2019)
"Treatment with fluoxetine for 7 days, but not 24 hours, also reinstated social interaction behavior in mice that were susceptible to chronic social defeat."	1.48	Reversal of Stress-Induced Social Interaction Deficits by Buprenorphine. ( Berton, O; Browne, CA; Falcon, E; Lucki, I; Robinson, SA, 2018)
" Records were also screened for adverse medical events and changes in ketamine dosage over time."	1.48	Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study. ( De Gioannis, A; Garrett-Walcott, S; Hartberg, J, 2018)
"Post-traumatic stress disorder (PTSD) is commonly associated with concurrent anxiety and depression symptoms, and reduce the expression of the Brain-Derived Neurotrophic Factor (BDNF) which promotes the proliferation and survival of neurons."	1.48	Applying ketamine to alleviate the PTSD-like effects by regulating the HCN1-related BDNF. ( Du, Z; Hou, L; Li, Q; Qi, Y; Sun, H; Sun, L; Wang, G; Wang, Y; Zhang, Z, 2018)
"35 (20%) in the no PTSD group (p < 0."	1.46	A retrospective study of ketamine administration and the development of acute or post-traumatic stress disorder in 274 war-wounded soldiers. ( Granier, C; Hoffmann, C; Le Masson, J; Mion, G, 2017)
"We have developed an animal model of PTSD, based on conditioning of the rabbit's eyeblink response, that addresses two key features: conditioned responses (CRs) to cues associated with an aversive event and a form of conditioned hyperarousal referred to as conditioning-specific reflex modification (CRM)."	1.46	Effects of systemic glutamatergic manipulations on conditioned eyeblink responses and hyperarousal in a rabbit model of post-traumatic stress disorder. ( Burhans, LB; Schreurs, BG; Smith-Bell, CA, 2017)
"To mimic PTSD we employed the inescapable footshock protocol."	1.46	Ketamine promotes increased freezing behavior in rats with experimental PTSD without changing brain glucose metabolism or BDNF. ( Bertoldi, K; Costa Da Costa, J; Greggio, S; Jeckel, CMM; Mestriner, RG; Neves, LT; Saur, L; Schallenberger, B; Siqueira, IR; Venturin, GT; Xavier, LL, 2017)
"Post-traumatic stress disorder (PTSD) displays high co-morbidity with major depression and treatment-resistant depression (TRD)."	1.46	Exploring a post-traumatic stress disorder paradigm in Flinders sensitive line rats to model treatment-resistant depression II: response to antidepressant augmentation strategies. ( Brand, SJ; Harvey, BH, 2017)
"Corticosterone levels were significantly suppressed by ketamine only in the exposed animals."	1.40	Immediate ketamine treatment does not prevent posttraumatic stress responses in an animal model for PTSD. ( Cohen, H; Juven-Wetzler, A; Kaplan, Z; Kohen, A; Porat, O; Zohar, J, 2014)
"Ketamine has been used in anesthesia for many years and in various environments with an acceptable safety margin."	1.39	Effects of ketamine on major depressive disorder in a patient with posttraumatic stress disorder. ( Womble, AL, 2013)
"Current PTSD symptoms were substantially elevated in (S)-ketamine subjects, while there was no difference observed between opioids and racemic ketamines."	1.33	Effects of peritraumatic ketamine medication on early and sustained posttraumatic stress symptoms in moderately injured accident victims. ( Badke, A; Domes, G; Hautzinger, M; Reichwald, U; Schönenberg, M, 2005)

Research

Studies (69)

Authors

Clinical Trials (22)

Trial Overview

Trial Outcomes

Montgomery-Asberg Depression Rating Scale (MADRS)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (5.80)	29.6817
2010's	32 (46.38)	24.3611
2020's	33 (47.83)	2.80

Authors	Studies
Abdallah, CG	3
Roache, JD	3
Gueorguieva, R	2
Averill, LA	3
Young-McCaughan, S	2
Shiroma, PR	4
Purohit, P	1
Brundige, A	1
Murff, W	1
Ahn, KH	1
Sherif, MA	1
Baltutis, EJ	1
Ranganathan, M	1
D'Souza, D	1
Martini, B	2
Southwick, SM	3
Petrakis, IL	1
Burson, RR	1
Guthmiller, KB	1
López-Roca, AL	2
Lautenschlager, KA	1
McCallin, JP	1
Hoch, MB	1
Timchenko, A	1
Souza, SE	1
Bryant, CE	1
Mintz, J	2
Litz, BT	2
Williamson, DE	2
Keane, TM	2
Peterson, AL	2
Krystal, JH	5
Bentley, S	1
Artin, H	1
Mehaffey, E	1
Liu, F	1
Sojourner, K	1
Bismark, A	1
Printz, D	1
Lee, EE	1
Martis, B	1
De Peralta, S	1
Baker, DG	1
Mishra, J	1
Ramanathan, D	1
Jumaili, WA	1
Trivedi, C	1
Chao, T	1
Kubosumi, A	1
Jain, S	1
Asim, M	2
Hao, B	2
Waris, A	1
Liang, YM	1
Wang, XG	1
Albott, CS	1
Lim, KO	1
Erbes, C	2
Thuras, P	2
Wels, J	2
Tye, SJ	1
Zoladz, PR	1
Del Valle, CR	1
Goodman, CS	1
Dodson, JL	1
Smith, IF	1
Elmouhawesse, KM	1
Sparkman, HR	1
Naylor, MM	1
Hopson, EP	1
Velit-Salazar, MR	1
Vorobyov, Y	1
Albuquerque, TR	1
Macedo, LFR	1
Delmondes, GA	1
Rolim Neto, ML	1
Almeida, TM	1
Uchida, RR	1
Cordeiro, Q	1
Lisboa, KWSC	1
Menezes, IRA	1
Vogt, KM	1
Pryor, KO	1
Blecha, S	1
Zeman, F	1
Rohr, M	1
Dodoo-Schittko, F	1
Brandstetter, S	1
Karagiannidis, C	1
Apfelbacher, C	1
Bein, T	1
Philipp-Muller, AE	1
Stephenson, CJ	1
Moghimi, E	1
Shirazi, AH	1
Milev, R	1
Vazquez, G	1
Reshetukha, T	1
Alavi, N	1
A Maddah, S	1
Petrucci, E	1
Cofini, V	1
Pizzi, B	1
Sollecchia, G	1
Cascella, M	1
Stefano, N	1
Vittori, A	1
Marinangeli, F	1
Duek, O	1
Korem, N	1
Li, Y	2
Kelmendi, B	2
Amen, S	1
Gordon, C	1
Milne, M	1
Levy, I	1
Harpaz-Rotem, I	2
Hu, X	1
Liu, L	1
Wang, Z	1
Sun, Y	1
Li, Z	1
Zhou, G	1
Yue, K	1
Wang, L	1
Lian, B	1
Lu, G	1
Li, C	2
Sun, L	3
Zhao, Y	2
Shao, H	1
Wang, H	1
Li, H	1
Xue, Q	1
Hintzsche, K	1
Ross, C	1
Jain, R	1
Bonnett, CJ	1
Wolfson, P	1
Wei, MD	1
Wang, YH	1
Lu, K	1
Lv, BJ	1
Wang, Y	3
Chen, WY	1
Fallon, IP	1
Tanner, MK	1
Greenwood, BN	1
Baratta, MV	1
Jalali, A	1
Akbari, H	1
Bahreini, M	1
Mion, G	2
Le Masson, J	2
Granier, C	2
Hoffmann, C	2
Keizer, BM	1
Jones, JR	1
Kalpinski, RJ	1
Porcerelli, JH	1
Feder, A	5
Rutter, SB	3
Schiller, D	1
Charney, DS	5
Vermetten, E	1
Krediet, E	1
Bostoen, T	1
Breeksema, JJ	1
Schoevers, RA	1
van den Brink, W	1
Choi, KH	1
Berman, RY	1
Zhang, M	1
Spencer, HF	1
Radford, KD	1
Kehle-Forbes, S	1
Polusny, M	1
Morena, M	2
Colucci, P	1
Mancini, GF	1
De Castro, V	1
Peloso, A	2
Schelling, G	2
Campolongo, P	2
Costi, S	2
Collins, AB	2
Govindarajulu, U	1
Jha, MK	2
Horn, SR	2
Kautz, M	3
Corniquel, M	2
Collins, KA	3
Bevilacqua, L	1
Glasgow, AM	2
Brallier, J	2
Pietrzak, RH	2
Murrough, JW	5
Stein, MB	1
Simon, NM	1
Zhang, X	1
Du, Y	1
Sun, H	3
Zhang, W	1
Wang, A	1
Li, Q	2
Du, Z	2
Davis, MT	1
DellaGiogia, N	1
Maruff, P	1
Esterlis, I	1
Wang, B	1
Wang, X	1
Norbury, A	1
Shin, LM	1
Glue, P	1
Medlicott, NJ	1
Harland, S	1
Neehoff, S	1
Anderson-Fahey, B	1
Le Nedelec, M	1
Gray, A	1
McNaughton, N	1
Berardi, A	1
Valeri, D	1
Palmery, M	1
Trezza, V	1
Wilkinson, ST	1
Toprak, M	1
Turner, MS	1
Levine, SP	1
Katz, RB	1
Sanacora, G	2
Burhans, LB	1
Smith-Bell, CA	1
Schreurs, BG	1
Saur, L	1
Neves, LT	1
Greggio, S	1
Venturin, GT	1
Jeckel, CMM	1
Costa Da Costa, J	1
Bertoldi, K	1
Schallenberger, B	1
Siqueira, IR	1
Mestriner, RG	1
Xavier, LL	1
Duman, RS	2
Browne, CA	1
Falcon, E	1
Robinson, SA	1
Berton, O	1
Lucki, I	1
Hartberg, J	1
Garrett-Walcott, S	1
De Gioannis, A	1
Fattore, L	1
Piva, A	1
Zanda, MT	1
Fumagalli, G	1
Chiamulera, C	1
Pradhan, B	2
Mitrev, L	1
Moaddell, R	1
Wainer, IW	1
Hou, L	1
Qi, Y	1
Wang, G	1
Zhang, Z	1
Amoroso, T	1
Guthmiller, K	1
Lautenschlager, K	1
Highland, KB	1
Soumoff, AA	1
Spinks, EA	1
Kemezis, PA	1
Buckenmaier, CC	1
Banov, MD	1
Young, JR	1
Dunn, T	1
Szabo, ST	1
D'Andrea, D	1
Andrew Sewell, R	1
Womble, AL	1
Juven-Wetzler, A	1
Cohen, H	1
Kaplan, Z	1
Kohen, A	1
Porat, O	1
Zohar, J	1
Parides, MK	1
Perez, AM	2
Morgan, JE	1
Saxena, S	1
Kirkwood, K	1
Aan Het Rot, M	1
Lapidus, KA	2
Wan, LB	1
Iosifescu, D	1
McGhee, LL	2
Maani, CV	2
Garza, TH	2
Slater, TM	1
Petz, LN	1
Fowler, M	1
Zhang, LM	1
Zhou, WW	1
Ji, YJ	1
Zhao, N	1
Chen, HX	1
Xue, R	1
Mei, XG	1
Zhang, YZ	1
Wang, HL	1
Li, YF	1
Rasmussen, KG	1
Wilson, JT	1
Kluewer D'Amico, J	1
Makani, R	1
Parikh, T	1
Donoghue, AC	1
Roback, MG	1
Cullen, KR	1
Soleimani, L	1
DeWilde, KE	1
Iacoviello, BM	1
Lener, M	1
Kim, J	1
Stern, JB	1
Price, RB	1
Brallier, JW	1
Rodriguez, GJ	1
Goodman, WK	1
Iosifescu, DV	1
Brand, SJ	1
Harvey, BH	1
Girgenti, MJ	1
Ghosal, S	1
LoPresto, D	1
Taylor, JR	1
Cukor, J	1
Spitalnick, J	1
Difede, J	1
Rizzo, A	1
Rothbaum, BO	1
Schofield, J	1
Johnston, AM	1
de Mello, WF	1
Roffey, P	1
Thangathurai, D	1
Schönenberg, M	2
Reichwald, U	2
Domes, G	2
Badke, A	2
Hautzinger, M	2
Gaylord, KM	1
Black, IH	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
CAP-Ketamine for Antidepressant Resistant PTSD[NCT02655692]	Phase 2	163 participants (Actual)	Interventional	2016-04-18	Completed
Influence of Quality of Care and Individual Patient Characteristics on Quality of Life/ Return to Work in Survivors of the Acute Respiratory Distress Syndrome (ARDS): Prospective, Observational, Multi-centre Cohort Study[NCT02637011]		2,000 participants (Anticipated)	Observational	2014-09-30	Recruiting
(2R,6R)-Hydroxynorketamine a Novel Therapeutic Analgesic for the Treatment of Neuropathic Pain: A Randomized Double Blind Cross-Over Trial.[NCT05864053]	Phase 1/Phase 2	25 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
Repeated Sub-anesthetic Ketamine to Enhance Prolonged Exposure Therapy in Post-traumatic Stress Disorder: A Proof-of-concept Study[NCT03960658]	Phase 1/Phase 2	12 participants (Actual)	Interventional	2019-04-03	Completed
Connectivity Changes Associated With Ketamine Assisted Psychotherapy for PTSD[NCT06036511]	Phase 1/Phase 2	14 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Randomized Controlled Trial of Repeated-Dose Intravenous Ketamine for PTSD[NCT02397889]	Phase 2/Phase 3	30 participants (Actual)	Interventional	2015-05-18	Completed
Ketamine Infusion for Social Anxiety Disorder[NCT02083926]	Early Phase 1	18 participants (Actual)	Interventional	2015-01-02	Completed
Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy[NCT03889756]	Phase 2/Phase 3	3 participants (Actual)	Interventional	2019-07-17	Terminated (stopped due to No more funding available to continue since we could not recruit throughout the pandemic.)
Assessing a Combined Ketamine and Online Cognitive Behavioural Therapy Intervention for Treatment Resistant Post-Traumatic Stress Disorder[NCT04771767]	Phase 2	16 participants (Anticipated)	Interventional	2021-08-01	Recruiting
Ketamine Infusion Therapy for the Treatment of PTSD in Paramedics[NCT03947099]		7 participants (Actual)	Observational	2019-05-02	Completed
Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder[NCT00749203]	Phase 2	41 participants (Actual)	Interventional	2009-01-31	Completed
Low Dose Ketamine Infusion for Comorbid Posttraumatic Stress Disorder and Chronic Pain Patients[NCT04322968]	Phase 3	41 participants (Actual)	Interventional	2018-01-09	Completed
A Single Ketamine Infusion Combined With Music for Suicidal Ideation During a Depressive Episode: A Randomized Open Label Clinical Trial[NCT04658420]	Phase 2	200 participants (Anticipated)	Interventional	2021-07-01	Not yet recruiting
Music as a Potential Intervention to Improve Hemodynamic Tolerability of Repetitive Sub-Anesthetic IV Ketamine Infusions in Bipolar and Unipolar Depression: A Pilot Study[NCT04701866]		32 participants (Actual)	Interventional	2021-01-11	Completed
A Pilot Study to Assess the Efficacy of Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy[NCT05019885]	Phase 2	6 participants (Anticipated)	Interventional	2022-08-26	Recruiting
Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department[NCT04260607]	Phase 3	2 participants (Actual)	Interventional	2020-01-14	Terminated (stopped due to As a busy MTF we were unable to retain a health care provider with the appropriate expertise to buy-in to this study once the initiating PI left military service.)
The Effect of Therapeutic Ketamine Infusions on the Symptoms of Post-Traumatic Stress Disorder in Combat Veterans[NCT03088384]		30 participants (Actual)	Observational	2016-11-28	Completed
Open Study of the Neurobiological Effects of Intranasal Ketamine in Children and Adults With Bipolar Disorder - Fear of Harm Phenotype[NCT05209217]		20 participants (Anticipated)	Observational	2019-06-04	Recruiting
Ketamine and Mindfulness Based Cognitive Therapy (MBCT) in Treatment of Post-Traumatic Stress Disorder (PTSD): Comparison of Treatment Efficacy and Metabolomic Profiles[NCT02766192]		50 participants (Anticipated)	Interventional	2013-08-31	Recruiting
Pathophysiological Understanding and Treatment of PTSD: an rTMS Approach[NCT03840369]		25 participants (Actual)	Interventional	2020-06-01	Completed
Investigating Rapid Anti-Suicidal Ideation Effects of Intravenous (IV) Ketamine in Hospitalized Patients[NCT01507181]	Phase 4	24 participants (Actual)	Interventional	2012-01-31	Completed
ED Treatment of Suicidal Patients With Ketamine Infusion[NCT03502551]	Phase 2	0 participants (Actual)	Interventional	2019-04-01	Withdrawn (stopped due to Trial never received funding.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Montgomery-Asberg Depression Rating Scale (MADRS) is a clinician rated ten-item diagnostic questionnaire to measure the severity of depression. The overall score ranges from 0 to 60 (0 to 6 - normal/symptom absent; 7 to 19 mild depression; 20 to 34 - moderate depression; >34 - severe depression) (NCT02655692)
Timeframe: Follow-up 1 - Day 25

Montgomery-Asberg Depression Rating Scale (MADRS)

Intervention	score on a scale (Mean)
Placebo	15.98
Low Dose Ketamine	12.91
High Dose Ketamine	10.78

Intervention	score on a scale (Mean)
Placebo	24.00
Low Dose Ketamine	25.11
High Dose Ketamine	25.08

Intervention	score on a scale (Mean)
Placebo	15.00
Low Dose Ketamine	19.18
High Dose Ketamine	20.27

Intervention	score on a scale (Mean)
Placebo	16.08
Low Dose Ketamine	14.43
High Dose Ketamine	12.72

Intervention	score on a scale (Mean)
Placebo	16.89
Low Dose Ketamine	15.74
High Dose Ketamine	16.42

Intervention	score on a scale (Mean)
Placebo	19.60
Low Dose Ketamine	15.87
High Dose Ketamine	17.68

Intervention	score on a scale (Mean)
Placebo	19.45
Low Dose Ketamine	15.44
High Dose Ketamine	19.58

Intervention	score on a scale (Mean)
Placebo	28.24
Low Dose Ketamine	27.81
High Dose Ketamine	27.84

Intervention	score on a scale (Mean)
Placebo	17.75
Low Dose Ketamine	17.02
High Dose Ketamine	12.94

Intervention	score on a scale (Mean)
Placebo	19.98
Low Dose Ketamine	19.34
High Dose Ketamine	17.86

Intervention	score on a scale (Mean)
Placebo	19.94
Low Dose Ketamine	17.83
High Dose Ketamine	18.54

Intervention	score on a scale (Mean)
Placebo	20.70
Low Dose Ketamine	16.64
High Dose Ketamine	18.07

Intervention	score on a scale (Mean)
Placebo	18.36
Low Dose Ketamine	16.71
High Dose Ketamine	16.83

Intervention	score on a scale (Mean)
Placebo	17.02
Low Dose Ketamine	14.75
High Dose Ketamine	15.15

Intervention	score on a scale (Mean)
Placebo	17.02
Low Dose Ketamine	16.44
High Dose Ketamine	15.78

PTSD Checklist (PCL)

Intervention	score on a scale (Mean)
Placebo	17.11
Low Dose Ketamine	14.43
High Dose Ketamine	14.24

"The PTSD Checklist (PCL) is a brief measure of the symptoms of Posttraumatic Stress Disorder (PTSD) to measure change in PTSD symptoms. The PCL-5 is a 20-item self-report measure, a total symptom severity score (range - 0-80) is obtained by summing the scores for each of the 20 items. (5-point Likert (0 = Not at all to 4 = Extremely). A total symptom severity score (range 0-80) with higher scores indicating greater severity for PTSD" (NCT02655692)
Timeframe: Session 1 -Day 0

The PTSD Checklist (PCL)

Intervention	units on a scale (Mean)
Placebo	48.56
Low Dose Ketamine	46.62
High Dose Ketamine	47.88

Intervention	units on a scale (Mean)
Placebo	27.34
Low Dose Ketamine	21.35
High Dose Ketamine	22.54

Intervention	units on a scale (Mean)
Placebo	37.84
Low Dose Ketamine	34.59
High Dose Ketamine	39.58

Intervention	units on a scale (Mean)
Placebo	33.79
Low Dose Ketamine	33.72
High Dose Ketamine	40.27

Intervention	units on a scale (Mean)
Placebo	26.92
Low Dose Ketamine	22.84
High Dose Ketamine	24.09

Intervention	units on a scale (Mean)
Placebo	28.14
Low Dose Ketamine	25.62
High Dose Ketamine	29.16

Intervention	units on a scale (Mean)
Placebo	30.71
Low Dose Ketamine	24.90
High Dose Ketamine	30.21

Intervention	units on a scale (Mean)
Placebo	31.90
Low Dose Ketamine	24.32
High Dose Ketamine	31.23

Intervention	units on a scale (Mean)
Placebo	37.65
Low Dose Ketamine	32.75
High Dose Ketamine	30.10

Intervention	units on a scale (Mean)
Placebo	36.90
Low Dose Ketamine	33.66
High Dose Ketamine	34.20

Intervention	units on a scale (Mean)
Placebo	34.75
Low Dose Ketamine	29.09
High Dose Ketamine	32.58

Intervention	units on a scale (Mean)
Placebo	35.11
Low Dose Ketamine	28.51
High Dose Ketamine	31.46

Intervention	units on a scale (Mean)
Placebo	30.80
Low Dose Ketamine	26.40
High Dose Ketamine	27.91

Intervention	units on a scale (Mean)
Placebo	28.48
Low Dose Ketamine	24.13
High Dose Ketamine	26.54

Intervention	units on a scale (Mean)
Placebo	29.31
Low Dose Ketamine	24.52
High Dose Ketamine	26.73

Change in PTSD Symptoms for DSM-5

Intervention	units on a scale (Mean)
Placebo	28.31
Low Dose Ketamine	21.94
High Dose Ketamine	25.62

The PTSD Checklist for DSM-5 (PCL5) is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD. Range from 0-80. Higher values represent worse outcomes. (NCT03960658)
Timeframe: 10 weeks

Change in Severity of Depressive Symptoms

Intervention	score on a scale (Mean)
Ketamine and Prolonged Exposure	30.8

Total score on the Montgomery- Åsberg Depression Rating Scale , a semi- structured 10-item scale. Range 0-60. Higher values represent worse outcomes. The total score is obtained by summing the severity score of each item. (NCT03960658)
Timeframe: 10 weeks

Change in Severity of Post-traumatic Stress Disorder (PTSD) Symptoms

Intervention	units on a scale (Mean)
Ketamine and Prolonged Exposure	11.5

The overall severity of PTSD symptoms would be measured by the mean change in the Past Month (current) total scores on the Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (CAPS-5) from baseline to post-treatment (10 weeks). The CAPS-5 is a structured interview with higher values representing worse outcomes. The CAPS-5 total symptom severity score ranges from 0 to 80 and it is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms. (NCT03960658)
Timeframe: 10 weeks

Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)

Intervention	units on a scale (Mean)
Ketamine and Prolonged Exposure	15.3

full range score from 0-80, with higher scores indicating greater PTSD symptoms (NCT02397889)
Timeframe: 2 weeks after the first infusion

Montgomery Asberg Depression Rating Scale (MADRS)

Intervention	score on a scale (Mean)
Experimental Ketamine Group	22.5
Active Control Midazolam Group	33.2

full range score from 0-60, with higher scores indicating greater depressive symptoms (NCT02397889)
Timeframe: 2 weeks after the first drug infusion

Montgomery Asberg Depression Rating Scale (MADRS)

Intervention	score on a scale (Mean)
Experimental Ketamine Group	14.7
Active Control Midazolam Group	21.9

full range score from 0-60, with higher scores indicating greater depressive symptoms (NCT02397889)
Timeframe: 24 hours after the first drug infusion

Number of Participants With Patient-Rated Inventory of Side Effects (PRISE)

Intervention	score on a scale (Mean)
Experimental Ketamine Group	16.5
Active Control Midazolam Group	17.1

All side effects listed in Adverse Event section. (NCT02397889)
Timeframe: up to 21 weeks

Quick Inventory of Depression Symptomatology - Self-Report (QIDS-SR)

Intervention	Participants (Count of Participants)
Experimental Ketamine Group	15
Active Control Midazolam Group	15

full range score from 0-27, with higher scores indicating greater depressive symptoms (NCT02397889)
Timeframe: 2 weeks after the first drug infusion

The Impact of Event Scale - Revised (IES-R)

Intervention	score on a scale (Mean)
Experimental Ketamine Group	6.6
Active Control Midazolam Group	6.7

full range score from 0-88, with higher scores indicating greater PTSD symptoms (NCT02397889)
Timeframe: 24 hours after the first drug infusion

Liebowitz Social Anxiety Score (LSAS)

Intervention	score on a scale (Mean)
Experimental Ketamine Group	19.7
Active Control Midazolam Group	24.8

Clinician-administered scale for the assessment of fear and avoidance found in social phobia (SAD); it has 24 items divided into 2 subscales, 13 for performance anxiety, and 11 for social situations each rated from 0 to 3 (0=none,1=mild,2=moderate,3=definite). The sum scores for Fear and Avoidance results in an overall score (max 144 points). There are 4 clinician subscales: fear of social interaction, fear of performance, avoidance of social interaction and avoidance of performance 0 to 30= SAD is unlikely 30 to 60=SAD is probable 60 to 90=SADis very probable >90= SAD highly probable (NCT02083926)
Timeframe: Day 1 (1+28)

Visual Analogue Scale for Anxiety Symptoms (VAS-anxiety)

Intervention	score on a scale (Mean)
Ketamine Infusion on Day 0 or Day 28	66.1
Saline Infusion on Day 0 or Day 28	86.1

"Instrument that tries to measure anxiety, that is believed to range across a continuum of values and cannot easily be directly measured.We used a straight horizontal line of 100 mm in length. The ends were defined as the extreme limits of the parameter to be measured (anxiety); oriented from the left (no anxiety) to the right (worst anxiety ever felt). The patient marks on the line the point that they feel represents their perception of their current state.The VAS score is determined by measuring in millimeters from the left hand end of the line to the point that the patient marks.~We examined Visual Analog Scale (VAS) for anxiety symptoms at screening, 1 hour prior to infusion, 1, 2 and 3 hours after infusion, 1, 2, 3, 5, 7, 10, and 14 days following a single ketamine/saline infusion." (NCT02083926)
Timeframe: Day 1 (1+28)

Efficacy of a Multiple-dosing Ketamine Infusion Paradigm (2 Infusions Per Week for 3 Weeks) Compared to Midazolam in Adolescents With Treatment Resistant Depression Using the Children's Depression Rating Scale (CDRS)

Intervention	units on a scale (Mean)
Ketamine Infusion on Day 0 or Day 28	12.1
Saline Infusion on Day 0 or Day 28	19.6

Establish if repeated ketamine will be efficacious medically and psychiatrically, as measured by a significant reduction in CDRS score in those treated with ketamine at the end of the dosing paradigm. The Children's Depression Rating Scale (CDRS) is a clinician-rated instrument with 17 items scored on a 1 to 5 or 1 to 7 scale. A rating of 1 indicates normal, thus the minimum score is 17. The maximum score is 113. Scores of 20-30 suggest borderline depression. Scores of 40-60 indicate moderate depression. (NCT03889756)
Timeframe: Day 18

Tolerability of a Multiple-dosing Ketamine Infusion Paradigm (2 Infusions Per Week for 3 Weeks) Compared to Midazolam in Adolescents With Treatment Resistant Depression

Intervention	score on a scale (Mean)
Ketamine	42
Midazolam	62

Establish if repeated ketamine will be tolerated as measured by drop-out counts. (NCT03889756)
Timeframe: Day 18

Clinician-Administered PTSD Scale (CAPS)

Intervention	Participants (Count of Participants)
Ketamine	0
Midazolam	0

Clinician-administered structured interview measuring PTSD symptoms. frequency score - scale 0 = none of the time to 4 = most or all of the time intensity score - scale 0 = none to 4 = extreme To meet criteria for a symptom, a patient must meet criteria in both frequency and intensity score for each item. Frequency and intensity and then combined to form a single severity score. 30 questions scale, with total score ranging from 0 to 240. (NCT00749203)
Timeframe: 7 days after first infusion

Impact of Event Scale - Revised (IES-R)

Intervention	units on a scale (Mean)
Ketamine	54
Midazolam	65.69

"A 22-item self-report questionnaire measuring PTSD symptoms. Items are rated on a 5-point scale ranging from 0 (not at all) to 4 (extremely). The IES-R yields a total score ranging from 0 (not at all) to 88 (extremely)" (NCT00749203)
Timeframe: 7 days after first infusion

Montgomery-Asberg Depression Rating Scale (MADRS)

Clinician-administered questionnaire measuring depressive symptoms. The MADRS-S has 10-items which are based on mood symptoms over the past 7 days. Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression). Mean difference between baseline and 2 weeks. (NCT00749203)
Timeframe: 24 hours after first infusion

Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)

Self-report questionnaire measuring depressive symptoms. Each item is rated 0 (no depression) to 3 (severe depression). The total score ranges from 0-27. (NCT00749203)
Timeframe: 24 hours after first infusion

Impact of Event Scale-Revised (IES-R)

"Severity of PTSD symptoms; items are rated on a 5-point scale ranging from 0 (not at all) to 4 (extremely). The IES-R yields a total score (ranging from 0 to 88); higher scores mean worse symptoms" (NCT04322968)
Timeframe: 1 week post-infusion

Impact of Event Scale-Revised (IES-R)

Visual Analogue Scale (VAS)

"Severity of chronic pain symptoms; using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the no pain anchor and the patient's mark, providing a range of scores from 0-100; a higher score indicates greater pain intensity." (NCT04322968)
Timeframe: 1 week post-infusion

Visual Analogue Scale (VAS)

Brief Pain Inventory (Short Form)

"Severity of pain, impact of pain on daily function, location of pain, pain medications and amount of pain relief in the past 24 hours or the past week; No scoring algorithm, but worst pain or the arithmetic mean of the four severity items can be used as measures of pain severity (a range of 0-10, with 10 being worse scores); the arithmetic mean of the seven interference items can be used as a measure of pain interference (a range of 0-10, with 10 being worse scores). The total score is reported for severity items and interference items, which range from 0-40 and 0-70, respectively. Higher values represent worse outcome." (NCT04322968)
Timeframe: 1 week post-infusion

Change in Beck Scale for Suicidal Ideation (BSSI)

Change in BSI score at 24 hours following treatment as compared to baseline. Beck Scale is a 21-item self or clinician administered instrumentation used to measure the current intensity of patients' specific attitudes, behaviors and plans to commit suicide. Score range 0-42, with higher score indicating higher intensity. (NCT01507181)
Timeframe: baseline and 24 hours post infusion

Change in Beck Scale for Suicidal Ideation (BSSI)

Change in BSI score at 48 hours following treatment as compared to baseline. Beck Scale is a 21-item self or clinician administered instrumentation used to measure the current intensity of patients' specific attitudes, behaviors and plans to commit suicide. Score range 0-42, with higher score indicating higher intensity. (NCT01507181)
Timeframe: baseline and 48 hours post infusion

Patient Rated Inventory of Side Effects (PRISE)

The PRISE assesses the presence of treatment side effects in nine organ/function systems (gastrointestinal, nervous system, heart, eyes/ears, skin, genital/urinary, sleep, sexual functioning, and other). Data reported in in Adverse Events section. (NCT01507181)
Timeframe: duration of study

Suicidality Item of the MADRS (MADRS-SI)

The MADRS-SI ranges from 0 to 6; a score of 2 corresponds to fleeting, passive SI; a score of 4 indicates that SI is frequent with at least moderate intensity but without specific plans or intention; a score of 6 corresponds to active intention and planning for suicide. (NCT01507181)
Timeframe: 24 hours post infusion

Montgomery-Asberg Depression Rating Scale (MADRS)

The MADRS is a 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT01507181)
Timeframe: up to 7 days post infusion

The Brief Psychiatric Rating Scale (BPRS)

The BPRS measures psychomimetic effects with higher scores indicating more severe symptoms (scale range 7 - 49). (NCT01507181)
Timeframe: baseline, 40 minutes post infusion, and 240 minutes post infusion

The Clinician-Administered Dissociative States Scale (CADSS)

The CADSS measures dissociation with higher scores indicating more severe symptoms (scale range 0 - 92). (NCT01507181)
Timeframe: baseline, 40 minutes post infusion and 240 minutes post infusion

The Young Mania Rating Scale (YMRS)

An 11-item questionnaire, used to assess manic symptoms based on the patient's subjective report of his or her clinical condition. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. The scores from each question are added together to form a total score ranging from 0 to 60, with higher scores indicating a greater severity of symptoms. (NCT01507181)
Timeframe: baseline, 40 minutes post infusion, 240 minutes post infusion

Reviews

Trials

Other Studies

42 other studies available for ketamine and Acute Post-Traumatic Stress Disorder

Intervention	units on a scale (Mean)
Chronic Pain With PTSD+IV Ketamine Infusion	28.22
Chronic Pain With PTSD+IV Ketorolac Infusion	33.66666667
Chronic Pain Without PTSD+IV Ketamine Infusion	11.44
Chronic Pain Without PTSD+IV Ketorolac Infusion	13.41

Intervention	units on a scale (Mean)
Chronic Pain With PTSD+IV Ketamine Infusion	36.33333333
Chronic Pain With PTSD+IV Ketorolac Infusion	37
Chronic Pain Without PTSD+IV Ketamine Infusion	10.44444444
Chronic Pain Without PTSD+IV Ketorolac Infusion	15.64705882

Intervention	units on a scale (Mean)
Chronic Pain With PTSD+IV Ketamine Infusion	48.22
Chronic Pain With PTSD+IV Ketorolac Infusion	52.88
Chronic Pain Without PTSD+IV Ketamine Infusion	43.33
Chronic Pain Without PTSD+IV Ketorolac Infusion	48.23

Intervention	units on a scale (Mean)
Chronic Pain With PTSD+IV Ketamine Infusion	37.22222222
Chronic Pain With PTSD+IV Ketorolac Infusion	49.66666667
Chronic Pain Without PTSD+IV Ketamine Infusion	29.88888889
Chronic Pain Without PTSD+IV Ketorolac Infusion	38.70588235

Intervention	units on a scale (Mean)
	Pain interference Scale	Pain severity Scale
Chronic Pain With PTSD+IV Ketamine Infusion	38.62	20.75
Chronic Pain With PTSD+IV Ketorolac Infusion	25.66	14.66
Chronic Pain Without PTSD+IV Ketamine Infusion	9.62	12.75
Chronic Pain Without PTSD+IV Ketorolac Infusion	28.33	22.66

Intervention	units on a scale (Mean)
	24 hours	48 hours	72 hours	7 days
Ketamine	19.0	19.3	20.9	21.7
Midazolam	26.2	28	24.1	22.2

Intervention	units on a scale (Mean)
	baseline	40 minutes post infusion	240 minutes post infusion
Ketamine	7.7	9.9	8.1
Midazolam	7.7	7.9	7.0

Article	Year
The safety and efficacy of ketamine NMDA receptor blocker as a therapeutic intervention for PTSD review of a randomized clinical trial. Behavioural brain research, 2022, 04-29, Volume: 424 Topics: Antidepressive Agents; Humans; Ketamine; Randomized Controlled Trials as Topic; Receptors, N-Methyl-	2022
A Systematic Review of Neurocognitive Effects of Subanesthetic Doses of Intravenous Ketamine in Major Depressive Disorder, Post-Traumatic Stress Disorder, and Healthy Population. Clinical drug investigation, 2022, Volume: 42, Issue:7 Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Humans; Ketamine; Recept	2022
Evidence for the beneficial effect of ketamine in the treatment of patients with post-traumatic stress disorder: A systematic review and meta-analysis. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2022, Volume: 42, Issue:12 Topics: Cognitive Behavioral Therapy; Humans; Ketamine; Psychotherapy; Stress Disorders, Post-Traumatic	2022
Anesthesia and the neurobiology of fear and posttraumatic stress disorder. Current opinion in anaesthesiology, 2022, Oct-01, Volume: 35, Issue:5 Topics: Anesthesia; Fear; Humans; Hypnotics and Sedatives; Ketamine; Stress Disorders, Post-Traumatic	2022
Combining Ketamine and Psychotherapy for the Treatment of Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis. The Journal of clinical psychiatry, 2023, 02-06, Volume: 84, Issue:2 Topics: Humans; Ketamine; Psychotherapy; Stress Disorders, Post-Traumatic	2023
Subanesthetic-Dose Ketamine to Decrease Emergence Delirium in the Surgical Patient With Posttraumatic Stress Disorder. AANA journal, 2018, Volume: 86, Issue:3 Topics: Analgesics; Emergence Delirium; Humans; Injections, Subcutaneous; Intraoperative Period; Ketamine; N	2018
Sex differences in resilience: Experiential factors and their mechanisms. The European journal of neuroscience, 2020, Volume: 52, Issue:1 Topics: Animals; Brain; Female; Humans; Ketamine; Male; Sex Characteristics; Stress Disorders, Post-Traumati	2020
The emergence of ketamine as a novel treatment for posttraumatic stress disorder. Advances in pharmacology (San Diego, Calif.), 2020, Volume: 89 Topics: Animals; Antidepressive Agents; Disease Models, Animal; Humans; Ketamine; Practice Patterns, Physici	2020
[Psychedelics in the treatment of PTSD]. Tijdschrift voor psychiatrie, 2020, Volume: 62, Issue:8 Topics: Combined Modality Therapy; Hallucinogens; Humans; Ketamine; Psychotherapy; Stress Disorders, Post-Tr	2020
Effects of Ketamine on Rodent Fear Memory. International journal of molecular sciences, 2020, Sep-28, Volume: 21, Issue:19 Topics: Analgesics; Anesthetics, Dissociative; Animals; Depressive Disorder, Major; Drug Administration Rout	2020
Ketamine for post-traumatic stress disorders and it's possible therapeutic mechanism. Neurochemistry international, 2021, Volume: 146 Topics: Animals; Excitatory Amino Acid Antagonists; Humans; Ketamine; Receptors, N-Methyl-D-Aspartate; Stres	2021
Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic. Current psychiatry reports, 2017, Aug-26, Volume: 19, Issue:10 Topics: Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; Humans; Ketamine; Neurobiology;	2017
Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine. Psychopharmacology, 2018, Volume: 235, Issue:2 Topics: Anesthetics, Dissociative; Animals; Appetitive Behavior; Cannabinoids; Emotions; Hallucinogens; Huma	2018
Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: a review of the literature. CNS spectrums, 2020, Volume: 25, Issue:3 Topics: Anti-Anxiety Agents; Anxiety Disorders; Bipolar Disorder; Humans; Ketamine; Stress Disorders, Post-T	2020
Nonconventional interventions for chronic post-traumatic stress disorder: Ketamine, repetitive trans-cranial magnetic stimulation (rTMS), and alternative approaches. Journal of trauma & dissociation : the official journal of the International Society for the Study of Dissociation (ISSD), 2016, Volume: 17, Issue:1 Topics: Anesthetics, Dissociative; Chronic Disease; Cognitive Behavioral Therapy; Complementary Therapies; H	2016
Nonconventional interventions for chronic post-traumatic stress disorder: Ketamine, repetitive trans-cranial magnetic stimulation (rTMS), and alternative approaches. Journal of trauma & dissociation : the official journal of the International Society for the Study of Dissociation (ISSD), 2016, Volume: 17, Issue:1 Topics: Anesthetics, Dissociative; Chronic Disease; Cognitive Behavioral Therapy; Complementary Therapies; H	2016
Nonconventional interventions for chronic post-traumatic stress disorder: Ketamine, repetitive trans-cranial magnetic stimulation (rTMS), and alternative approaches. Journal of trauma & dissociation : the official journal of the International Society for the Study of Dissociation (ISSD), 2016, Volume: 17, Issue:1 Topics: Anesthetics, Dissociative; Chronic Disease; Cognitive Behavioral Therapy; Complementary Therapies; H	2016
Nonconventional interventions for chronic post-traumatic stress disorder: Ketamine, repetitive trans-cranial magnetic stimulation (rTMS), and alternative approaches. Journal of trauma & dissociation : the official journal of the International Society for the Study of Dissociation (ISSD), 2016, Volume: 17, Issue:1 Topics: Anesthetics, Dissociative; Chronic Disease; Cognitive Behavioral Therapy; Complementary Therapies; H	2016
Remission From Behavioral Dysregulation in a Child With PTSD After Receiving Procedural Ketamine. Pediatrics, 2015, Volume: 136, Issue:3 Topics: Child; Child Behavior Disorders; Excitatory Amino Acid Antagonists; Humans; Ketamine; Male; Remissio	2015
Emerging treatments for PTSD. Clinical psychology review, 2009, Volume: 29, Issue:8 Topics: Cognitive Behavioral Therapy; Combat Disorders; Computer Simulation; Cycloserine; Humans; Implosive	2009